Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results